Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Carolina Diclofenac 3% Coverage Update …
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    Actinic Keratosis - Score (Diclofenac Sodium GEL 3% and related step therapy policies)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines product-specific utilization management (step therapy) requirements for actinic keratosis topical therapy (Diclofenac Sodium GEL 3%) and several listed specialty drugs; impacts prescribers and pharmacy prior authorization reviewers.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyActinic Keratosis - Score (Diclofenac Sodium GEL 3% and related step therapy policies)
    Policy CodePolicy N/A
    Change TypeAdministrative — no material clinical changes
    Effective DateApr 1, 2026
    Last ReviewMar 2, 2026
    Next Review DateMar 2, 2026
    Key ActionDocument a trial of topical fluorouracil or topical imiquimod before requesting approval for Diclofenac Sodium GEL 3%.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1primary criterion: trial required
    1Diclofenac Sodium GEL 3% listed
    multipleother step policies

    Coverage Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Diclofenac Sodium GEL 3% — Initial coverage

    Covered when ALL of the following are met

    Primary criterion: Trial of either topical fluorouracil or topical imiquimod

    Required prior to approval of Diclofenac Sodium GEL 3%

    Invega Hafyera — Initial coverage for new starts

    Covered when ALL of the following are met

    Primary criterion: Trial of one of the following: Invega Sustenna or Invega Trinza (step applies to new starts only)

    Continuation of prior therapy is approved

    Relistor — Initial coverage

    Covered when ALL of the following are met

    Primary criterion: Trial of lubiprostone, Constulose, Enulose, Generlac, or lactulose

    Required prior to approval of Relistor

    Zonisade Suspension — Initial coverage

    Covered when ALL of the following are met

    Primary criterion: Trial of generic zonisamide capsule (step applies to new starts only)

    Continuation of prior therapy is approved

    No explicit exclusions for Diclofenac Sodium GEL 3% are listed in this policy. The product is included under the Actinic Keratosis policy but the document does not enumerate any conditions or populations that would be specifically excluded from consideration.

    The policy does not identify any conditions as explicitly not medically necessary. Instead, it defines step therapy requirements that must be met for coverage (for example, documentation of a trial of specified topical agents prior to approval).

    Initial Therapy Criteria

    inv-23: Diclofenac Sodium 3% initial therapy

    Initial therapy requirements for Diclofenac Sodium GEL 3%

    Initial therapy requirement: Trial of either topical fluorouracil or topical imiquimod must be documented

    Specified in Details section

    Continuation Criteria

    inv-24: Continuation approvals

    Continuation of prior therapy

    Continuation of prior therapy is approved for Invega Hafyera and Zonisade suspension without requiring the step for new starts

    As stated for respective products

    Provider Actions and Documentation Requirements

    Prior Authorization

    Prior trial required for Diclofenac 3%

    Diclofenac Sodium GEL 3% requires documentation that the patient has tried either topical fluorouracil or topical imiquimod before the product will be approved.

    Step Therapy

    Topical step required before Diclofenac

    For actinic keratosis, step therapy requires a trial of either topical fluorouracil or topical imiquimod before Diclofenac Sodium GEL 3% will be approved.

    Documentation Required

    Document trial of topical fluorouracil or imiquimod

    To meet the coverage criterion for Diclofenac Sodium GEL 3%, documentation must show a trial of either topical fluorouracil or topical imiquimod.

    Step Therapy

    Step trial required for new Invega Hafyera starts

    New starts for Invega Hafyera must have a documented trial of either Invega Sustenna or Invega Trinza; members already on Invega Hafyera may be approved to continue prior therapy.

    Step Therapy

    Invega Hafyera step: alternate Invega product required

    Step therapy for Invega Hafyera mandates a trial of an alternate Invega product (Invega Sustenna or Invega Trinza) for new starts; continuation of prior therapy is approved.

    Documentation Required

    Document trial of Sustenna or Trinza for Invega Hafyera

    For new starts of Invega Hafyera, documentation must confirm a trial of Invega Sustenna or Invega Trinza; continuation of prior Invega Hafyera therapy may be approved without re‑stepping.

    Prior Authorization

    Laxative trial required for Relistor

    Approval of Relistor requires a prior trial of listed laxatives before authorization will be granted.

    Step Therapy

    Relistor step: try listed laxatives first

    Step therapy for Relistor requires a trial of one of the listed laxatives (lubiprostone, Constulose, Enulose, Generlac, or lactulose) prior to approval.

    • Lubiprostone
    • Constulose
    • Enulose
    • Generlac
    • Lactulose
    Documentation Required

    Document laxative trial for Relistor

    Documentation for Relistor requests must show a trial of one of the specified laxatives (lubiprostone, Constulose, Enulose, Generlac, or lactulose).

    • Lubiprostone
    • Constulose
    • Enulose
    • Generlac
    • Lactulose
    Step Therapy

    Generic zonisamide trial required for new Zonisade starts

    New starts of Zonisade Suspension require a trial of a generic zonisamide capsule before Zonisade will be approved; members already receiving Zonisade may continue therapy.

    Step Therapy

    Zonisade step: generic zonisamide required for new starts

    Step therapy for Zonisade Suspension mandates a trial of a generic zonisamide capsule for new starts; continuation of prior therapy is approved without requiring the step.

    Documentation Required

    Document trial of generic zonisamide for Zonisade

    For Zonisade suspension new starts, documentation must demonstrate a trial of a generic zonisamide capsule; prior therapy continuation may be approved without this requirement.

    Denial Risk

    Denial risk if topical trial not documented

    If a trial of either topical fluorouracil or topical imiquimod is not documented, authorization for Diclofenac Sodium GEL 3% for actinic keratosis may be denied.

    Denial Risk

    Denial risk for missing step therapy documentation

    For the specialty products listed (Invega Hafyera, Relistor, Zonisade), lack of documented trials of the specified alternative agents for new starts may result in denial of the requested product.

    • Invega Hafyera — trial of Invega Sustenna or Invega Trinza required for new starts
    • Relistor — trial of lubiprostone, Constulose, Enulose, Generlac, or lactulose required
    • Zonisade — trial of generic zonisamide capsule required for new starts

    Step Therapy Table

    DrugStep requirement
    Diclofenac Sodium GEL 3%
    Trial of either topical fluorouracil or topical imiquimod must be documented prior to approval
    DrugStep requirementApplies to
    Invega Hafyera
    Trial of one of the following: Invega Sustenna or Invega Trinza must be documented
    New starts only; continuation of prior therapy approved
    DrugStep requirement
    Relistor
    Trial of lubiprostone, Constulose, Enulose, Generlac, or lactulose must be documented prior to approval
    DrugStep requirementApplies to
    Zonisade Suspension
    Trial of a generic zonisamide capsule must be documented prior to approval
    New starts only; continuation of prior therapy approved

    Definitions

    Trial (policy definition)
    DefinitionAn attempted course of therapy with an alternative topical agent (topical fluorouracil or topical imiquimod) as specified in the policy prior to approval of Diclofenac Sodium GEL 3%.
    Required step before Diclofenac 3%Documentation of a trial of either topical fluorouracil or topical imiquimod is required prior to approval.
    Applicable indicationActinic keratosis — step therapy applies to topical treatment prior to Diclofenac Sodium GEL 3%.
    Denial riskFailure to document the required trial of topical fluorouracil or topical imiquimod may lead to denial of coverage for Diclofenac Sodium GEL 3%.

    Background

    Actinic keratosis is a common sun-related precancerous skin lesion treated with topical field therapies. This policy notes that first-line topical field agents include topical fluorouracil and topical imiquimod, and it requires a documented trial of one of these agents before approving alternative topical therapy such as Diclofenac Sodium GEL 3%.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyActinic Keratosis - Score (Diclofenac Sodium GEL 3% and related step therapy policies)
    Policy CodePolicy N/A
    Change TypeAdministrative — no material clinical changes
    Effective DateApr 1, 2026
    Last ReviewMar 2, 2026
    Next Review DateMar 2, 2026
    Key ActionDocument a trial of topical fluorouracil or topical imiquimod before requesting approval for Diclofenac Sodium GEL 3%.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation CriteriaProvider Actions and Documentation RequirementsStep Therapy TableDefinitionsBackground